• Dr. Amara graduated from the Medical College of Georgia with MD and PhD, with distinction. She then completed neurology residency as well as fellowship training in Movement Disorders and Sleep Medicine at the University of Alabama at Birmingham (UAB). She is currently as Associate Professor at UAB.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Motor phenotype classification in moderate to advanced PD in BioFIND studyParkinsonism and Related Disorders.  65:178-183. 2019
    2019 Self-reported physical activity levels and clinical progression in early Parkinson's diseaseParkinsonism and Related Disorders.  61:118-125. 2019
    2019 Feasibility and utility of a clinician dashboard from wearable and mobile application Parkinson's disease data.npj Digital Medicine.  2:95. 2019
    2019 Widespread tau-specific CD4 T cell reactivity in the general populationJournal of Immunology.  203:84-92. 2019
    2018 The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortAnnals of Clinical and Translational Neurology.  5:1460-1477. 2018
    2018 Deep brain stimulation and sleep-wake disturbances in parkinson disease: A reviewFrontiers in Neurology.  9. 2018
    2018 Transform with no Parameters Based on Extrema Points for Non-stationary Signal AnalysisCircuits, Systems, and Signal Processing.  37:2535-2547. 2018
    2018 Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease FeaturesMovement Disorders.  33:282-288. 2018
    2018 A feasibility study of combined intermittent theta burst stimulation and modified constraint-induced aphasia therapy in chronic post-stroke aphasiaRestorative Neurology and Neuroscience.  36:503-518. 2018
    2018 Effects of Exercise on Non-motor Symptoms in Parkinson's DiseaseClinical Therapeutics.  40:8-15. 2018
    2017 High-intensity exercise acutely increases substantia nigra and prefrontal brain activity in parkinson’s diseaseMedical Science Monitor.  23:6064-6071. 2017
    2017 Pedestrian safety in patients with Parkinson's disease: A case-control studyMovement Disorders.  32:1748-1755. 2017
    2017 A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015Sleep Medicine Reviews.  35:33-50. 2017
    2017 Longitudinal assessment of excessive daytime sleepiness in early Parkinson's diseaseJournal of Neurology, Neurosurgery and Psychiatry.  88:653-662. 2017
    2017 Treatment of Sleep Dysfunction in Parkinson’s DiseaseCurrent Treatment Options in Neurology.  19. 2017
    2017 The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's diseaseBrain Stimulation.  10:651-656. 2017
    2017 Effects of Subthalamic Nucleus Deep Brain Stimulation on Objective Sleep Outcomes in Parkinson's DiseaseMovement Disorders Clinical Practice.  4:183-190. 2017
    2016 The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohortMovement Disorders.  31:924-932. 2016
    2016 Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: Presentation, treatment and outcomesEpileptic Disorders.  18:34-43. 2016
    2016 Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorderParkinsonism and Related Disorders.  27:102-106. 2016
    2015 Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control studyMovement Disorders.  30:1371-1381. 2015
    2015 Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: A cross-sectional surveyBMJ Open.  5. 2015
    2013 The relationship between clinical phenotype and early staged bilateral deep brain stimulation in Parkinson disease: Clinical articleJournal of Neurosurgery.  119:1530-1536. 2013
    2013 Metabolomics and the search for biomarkers in Parkinson's diseaseMovement Disorders.  28:1620-1621. 2013
    2012 Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's diseaseParkinsonism and Related Disorders.  18:63-68. 2012
    2011 Challenges in diagnosis of isolated central nervous system vasculitisBrain and Behavior.  1:57-61. 2011
    2011 The effects of deep brain stimulation on sleep in Parkinson’s diseaseTherapeutic Advances in Neurological Disorders.  4:15-24. 2011
    2004 Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genesOncogene.  23:2330-2338. 2004
    2003 p73 can suppress the proliferation of cells that express mutant p53Oncogene.  22:5481-5495. 2003
    2003 Characterization of p73 functional domains necessary for transactivation and growth suppressionOncogene.  22:4333-4347. 2003
    2003 Isolation and characterization of fourteen novel putative and nine known target genes of the p53 familyCancer Biology and Therapy.  2:56-63. 2003
    2002 The promise and obstacle of p53 as a cancer therapeutic agentCurrent Molecular Medicine.  2:329-345. 2002
    1999 The biochemical role of glutamine 188 in human galactose-1-phosphate uridyltransferaseJournal of Biological Chemistry.  274:6559-6566. 1999


    Year Title Altmetric
    2015 Impact of surgical therapies on sleep and alertness in Parkinson’s disease.  195-207. 2015

    Research Overview

  • My major research interests include investigation of the impact of exercise on sleep, cognition, motor outcomes, and functional connectivity in patients with Parkinson’s disease. I have also investigated the influence of deep brain stimulation and other therapies on sleep in these patients. My lab also studies the effects of cognitive training (speed of processing training) on pedestrian safety, cognition, and visual processing in patients with Parkinson’s disease and healthy older adults. In addition, I am site investigator for multi-site studies evaluating biomarkers and investigational therapies in patients with Parkinson’s disease and dementia with Lewy bodies.
  • Investigator On

  • The Parkinson's Progression Marker's Initiative (PPMI)  awarded by Fox (Michael J.) Foundation for Parkinson's Research 2010 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Innate and Adaptive Immunity in Parkinson Disease - Core B: Clinical Research Core  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Interactions of Gut Microbiome, Genetic Susceptibility and Environmental Factors in Parkinson's Disease  awarded by DOD - Department of Defense 2018 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson’s Disease (PD)  awarded by Northwestern University 2018 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2021
  • Restless Legs Syndrome and Physical Activity in Adults With Multiple Sclerosis  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2019 - 2020
  • Center for Translational Research on Aging and Mobility - Core B: Pilot Core  awarded by National Institute on Aging/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by FUSION HEALTH LLC 2019 - 2020
  • Private Grant  awarded by BIOGEN IDEC, INC. 2018 - 2019
  • The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson Disease Foundation  awarded by National Parkinson Foundation, Inc. 2017 - 2019
  • Sleep for Stroke Management and Recovery Trial (Sleep SMART) Stroke Trial  awarded by University of Cincinnati 2018 - 2019
  • Phase 3 Trial of Inosine for Parkinson's Disease CCC  awarded by MASSACHUSETTS GENERAL HOSPITAL 2015 - 2019
  • Center for Translational Research on Aging and Mobility  awarded by National Institute on Aging/NIH/DHHS 2014 - 2019
  • SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2015 - 2019
  • Post-Stroke Aphasia and rTMS Treatment (PART) Study  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2012 - 2018
  • Private Grant  awarded by SERINA THERAPEUTICS 2015 - 2017
  • Private Grant  awarded by ABBVIE INC 2012 - 2016
  • Private Grant  awarded by PHARMA TWO B. LTD 2014 - 2015
  • Private Grant  awarded by Solvay Pharmaceuticals, Inc. 2010 - 2014
  • Private Grant  awarded by IMPAX LABORATORIES, INC. 2012 - 2013
  • Education And Training

  • University of Alabama at Birmingham, Postdoctoral Fellowship
  • Doctor of Medicine, Medical College of Georgia 2005
  • Doctor of Philosophy, Medical College of Georgia 2003
  • Bachelor's Degree in Medicine, Agnes Scott College 1998
  • UAB Hospital, Internship 2006
  • UAB Hospital, Residency 2009
  • UAB Hospital, Postdoctoral Fellowship 2011
  • UAB Hospital, Postdoctoral Fellowship 2010
  • Full Name

  • Amy Amara